Phase 2 N=64 SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Endometrial Cancer
Primary: Objective Response Rate (ORR) — 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=124 A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
Diffuse Large-Cell Lymphoma
Primary: Response Rate — 24; 28; 20; 22 Participants
Phase 2 N=6 Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
Classic Galactosemia
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 0; 2 Participants
Phase 2 N=39 Hepatocyte Growth Factor to Improve Functioning in PAD
Peripheral Artery Disease
Primary: Six-minute Walk Distance — 17.01; 3.46 meters — p=0.7586
Phase 2 N=27 The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
Asthma, COPD
Primary: Effect of FP-025 Versus Placebo on the Allergen (HDM)-Induced Late Asthmatic Response (LAR) in Subjects With Clinically Stable, Mild Allergic Asthma and Blood…
Phase 2 N=70 Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Primary: Number of Adverse Events in Participants — 6; 64 Participants
Phase 2 N=28 Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
Glioblastoma
Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 1 Participants
Phase 2 N=80 Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
Cardiac Catheterization · Blood Pressure · Heart Ventricles
Primary: Agreement Between SHAPE and Pressure Catheter Measurements — -0.8; -0.8 Correlation coefficient value
Phase 2 N=48 Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage I Adult Diffuse Large Cell Lymphoma
Primary: Recommended Phase II Dose (Phase I) — 20; 56 mg/m^2
Phase 2 N=123 Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Metastatic Soft Tissue Sarcoma · Locally Advanced Soft Tissue Sarcoma · Unresectable Soft Tissue Sarcoma
Primary: Progression-free Survival — 83; 170 Days
Phase 2 N=37 Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Child-Pugh Class A · Stage III Hepatocellular Carcinoma
Primary: Overall Response Rate Defined as Partial or Complete Response Per Immune-related Response Evaluation Criteria in Solid Tumors — 8; 19 Participants
Phase 2 N=29 Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Advanced Stage Non-small Cell Lung Cancer
Primary: Best Overall Response Rate (Confirmed Partial + Complete Response) Will be Assessed as Part of This Study. Tumor Response Will be Assessed Using RECIST 1.1) — 7; 5; 5…
Phase 2 N=71 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Non-alcoholic Steatohepatitis
Primary: Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks — 10.6; 29.2…
Phase 2 N=79 Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Presbyopia
Primary: Mean Change From Baseline in Binocular Distance Corrected Near Visual Acuity (DCNVA) — 4.1; 4.3; 4.4 EDTRS letters
Phase 2 N=65 Technology Enhanced Family Treatment
Mood Disorders · Bipolar Disorder · Major Depression
Primary: Average Depression Symptom Scores Over 27 Weeks on the Adolescent Longitudinal Interval Follow-up Evaluation — 3.39; 3.09 score on a scale